A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
32actual
Sites
1
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-13 | actual | When the study began enrolling |
| Primary completion | 2026-07-02 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-02 | actual | The whole study's end, after follow-up |
| First posted | 2026-03-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Participants
Interventions
- Drug: AZD5004
- Drug: Mitiglinide
- Drug: Pioglitazone
Primary outcomes
what the primary-completion date above is the date OFArea under concentration-time curve from time 0 to infinity (AUCinf)
measured Part A: From Day 1 to Day 50; Part B: From Day 1 to Day 70
Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)
measured Part A: From Day 1 to Day 50; Part B: From Day 1 to Day 70
Maximum observed drug concentration (Cmax)
measured Part A: From Day 1 to Day 50; Part B: From Day 1 to Day 70
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed